Navigation Links
Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)

SAN FRANCISCO, Sept. 9 /PRNewswire/ -- Epiphany Biosciences, Inc. today announced that a Phase 2b dose-ranging study to evaluate the safety, efficacy, and tolerability of the company's lead compound, valomaciclovir (EPB-348) in patients with acute herpes zoster infection (shingles), will continue as originally designed following an interim analysis.

Fred Volinsky, MD, Epiphany's CEO said, "We are pleased with the progress of this clinical trial and look forward to the final data. If successful, valomaciclovir will mark an advance in the treatment of herpes zoster which affects more than two million people annually around the globe. As the world population ages, it is expected that the incidence of this disease will grow significantly, especially in lieu of the lackluster response to vaccines in this area. We look to valomaciclovir to enhance the treatment experience by being the first once-daily therapy for shingles." The Phase 2b study is being conducted at sites throughout North America and uses an active comparator, valacyclovir. Outcomes assessed include various efficacy parameters including time to vesicular resolution and safety data collection.

In addition to the Phase 2b zoster study, valomaciclovir will also be studied in a separate Phase 2 clinical trial as a therapy in managing the most severe sequelae of a herpes-zoster infection, post-herpetic neuralgia or PHN. "The spectrum of disease caused by herpes viruses is underappreciated but a disease like shingles can have a profound impact on the quality-of-life of patients, many times leading to severe pain syndromes that could have a viral etiology. We look forward to examining the clinical utility of valomaciclovir in multiple conditions associated with herpes viruses and plan to maximize the broad-acting antiviral profile of this drug," reported Brian Murphy, MD, Chief Medical Officer of Epiphany.

In addition to the studies directed at herpes zoster, valomaciclovir is also being studied in a Phase 2 trial of acute infectious mononucleosis, a syndrome commonly seen in adolescents and young adults, caused by Epstein-Barr virus (EBV), also a member of the herpes virus family. "Further studies of valomaciclovir outside herpes zoster are warranted and we plan to examine uses of this drug in major diseases associated with EBV," commented Dr. Murphy.

Epiphany Biosciences is a privately-held company developing therapeutic products and diagnostic technologies that treat or help prevent the spread of pathogenic viruses, including varicella virus (VZV), Epstein-Barr virus (EBV) and hepatitis C virus (HCV).

Fred Volinsky, CEO

415 765 7193

SOURCE Epiphany Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
2. Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
3. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
7. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
8. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
9. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
10. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
11. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
Post Your Comments:
(Date:11/30/2015)... Next week, December 2-3, BIOMEDevice San ... co-located events covering the latest in Medtech innovation, Wearable ... draw more than 3,000 design industry professionals to the ... events, combined show floor will host more than 300 ... --> --> BIOMEDevice features suppliers in ...
(Date:11/30/2015)...  IBA Molecular North America, Inc. (IBAMNA), a U.S. ... that as of January 1, 2016, it will do ... to rebrand the company reflects a refined vision for ... close relationship with Zevacor Molecular.  Both IBAMNA and Zevacor ... Peter Burke , Vice President Sales ...
(Date:11/30/2015)... , Nov. 30, 2015 Nautilus Medical Inc. ... Image Management platform ( ). The release of ... from RSNA 2015 (Radiology Society North America) in ... in the U.S. --> ... that enables access to radiology studies worldwide via a ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... , ... RoamRight, a leading provider of travel insurance and a division of ... to promote family vacations around the world. The television show, which is in ... families about the people and places of the world, all while helping parents navigate ...
(Date:11/30/2015)... ... November 30, 2015 , ... Advocare Orthopedic and Sports ... Led by John Vitolo, M.D., the center offers their patients the highest ... Advocare Orthopedic & Sports Medicine is ready to help their patients return to ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... new study by UPMC and KingMed Diagnostics researchers. Their ... years found that consultation with UPMC pathologists resulted in significantly altered treatment plans ...
(Date:11/30/2015)... ... 30, 2015 , ... The American Society for Clinical Pathology (ASCP) announced today ... 2015. On Nov. 30, ASCP shared its “Give a minute. Get tested. Find a ... the importance of getting tested for HIV. , ASCP has asked members to replace ...
(Date:11/30/2015)... , ... November 30, 2015 , ... An inventor from ... in the womb. "My last baby had high blood pressure due to loud noises," ... to protect their babies from noise pollution as well as radio waves and microwaves." ...
Breaking Medicine News(10 mins):